EMA Helps Trial Sponsors Categorize IMP Changes Under New Rules
EU CTR Introduces Concept Of Non-Substantial Changes Relevant For Supervision
Executive Summary
The European Medicines Agency is inviting feedback on changes to two guidelines that will help trial sponsors correctly classify quality-related changes to their investigational medicinal products as per the requirements of the EU Clinical Trial Regulation.
You may also be interested in...
Long-Awaited EU Clinical Trials Portal Meets Major Milestone
A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.